Health care is nearly one in every five dollars spent in the U.S. economy. That is a big number, and it explains why a small price change in a clinic or a pharmacy can feel as loud as a jump at the grocery checkout. Prices for medical care do not move like a carton of eggs, though. Several payers share the bill, and several rules shape it.

Close-up of a folded paper pharmacy bag and a printed receipt on a worn counter in soft side light, showing where a prescription's cost reaches a household.
A pharmacy counter with a paper bag and a printed receipt, showing the point where a drug's price reaches a household.

Why health care costs weigh so heavily on household budgets

The bill is split. Federal government pays about 31 percent of national health spending, state and local governments 16 percent, employers 18 percent, and individuals about 6 percent. Other payers cover the rest. That 6 percent looks small. It is not the whole household story, because families also pay premiums and often see the cost in a paycheck, not a receipt.

Consider the 2023 employer-coverage example from the Peterson-KFF Health System Tracker. A family of four contributed $6,296 in premiums and incurred $3,564 in out-of-pocket spending that year. Think of it as two rent notices arriving from different landlords. One is deducted before you see your pay. The other shows up after each visit or prescription.

Public opinion data cited in the same analysis of 2026 health care cost trends name health care at the center of the affordability worry, ahead of food, rent, and utilities. Some of the pressure also comes from policy, not only from general inflation. Enhanced Affordable Care Act tax credits expired, and that led to significantly higher premium payments for millions of Marketplace enrollees.

How the Medicare inflation rebate program works

The Inflation Reduction Act created the Medicare Prescription Drug Inflation Rebate Program. The idea is simple. If the price of certain drugs rises faster than general inflation, the manufacturer pays a rebate to Medicare. Those rebates go to the Medicare Trust Fund. A rebate is a refund of part of the price, paid back after the fact.

There is a second feature that reaches patients more directly. People with Medicare may pay a lower coinsurance for some Part B drugs when the drug's price grows faster than inflation. Coinsurance is your percentage share of a cost, as opposed to a flat copay. Part B generally covers drugs a clinician administers. CMS has said it will keep applying these lower coinsurances, and it has lowered them for 64 drugs and biologicals so far.

Timing matters here. The Part D rebate period began October 1, 2022, and the Part B period began January 1, 2023. CMS plans to invoice manufacturers starting in 2025, covering 2022 through 2024. So the rebates lag the price increases by years.

The rules took shape in steps. CMS issued initial guidance in February 2023, analyzed more than 90 comments, and released revised guidance on December 14, 2023. That revised guidance sets out how rebates are calculated and how manufacturers are invoiced.

For a sense of scale, CMS listed 48 Part B drugs whose coinsurance could be lower from January 1 to March 31, 2024. Savings ranged from $1 to $2,786 per average dose. That spread is wide. It depends on individual coverage, so one person's result says little about another's.

Reading the spending projections carefully

Projections deserve measured skepticism. CMS actuaries and economists build them each year from National Health Expenditure models. The Peterson-KFF summary says total U.S. health spending could reach $6.0 trillion in 2026, or 18.7 percent of the economy. By 2034 it could reach $9.0 trillion, or 20.6 percent. Hospitals are the largest category, at $1.9 trillion in 2026 and a projected $2.7 trillion in 2034.

The growth rates tell a month-over-month kind of story, just stretched across years. Total spending is projected to rise 6.3 percent in 2026 and 4.7 percent in 2027. Retail prescription drug spending is projected to rise 8.2 percent in 2026, after an estimated 11.1 percent in 2025, then average 4.8 percent a year from 2027 to 2034. A slower rate is still growth. Prices are not falling in that picture.

One caution is easy to miss. Retail drug figures leave out drugs given by physicians in offices, hospitals, outpatient centers, long-term care facilities, and at home. Trends for those drugs may differ, so do not assume they track the retail line. And every number for 2026 and later is a projection, not a result. Projections change when conditions change.

Questions consumers can ask about their own drug costs

Start with the program. Is the drug under Part B, which usually covers drugs a clinician administers, or Part D, which usually covers drugs dispensed at a pharmacy? Different rules apply to each. The lower coinsurance discussed above is a Part B feature.

  • Is the drug on the CMS list for the relevant period? Lower coinsurance applies only to listed drugs and listed dates.
  • Was it given in a physician office or hospital, or dispensed at retail? That decides which data and rules are relevant.
  • What would my own coinsurance be under my plan?

This article is educational. It is not advice for your situation. For specific coverage questions, contact your plan, your prescriber, or Medicare directly, and check official CMS pages for current lists.

What the current sources do not cover

Some gaps are worth naming. The sources reviewed do not explain how the Consumer Price Index measures medical care prices. The Bureau of Labor Statistics has a factsheet on medical care in the CPI, and readers should read it directly before assuming a method.

They also do not give a current, complete list of drugs under rebates or lower coinsurance beyond the early-2024 list. A CMS document for early 2025 did not come through as readable text. They do not compare general inflation with medical price inflation over recent years, so any claim about which is rising faster is unverified here.

Finally, the material does not describe how a consumer checks personal coinsurance or out-of-pocket totals. A KFF note on public opinion about drug prices did not include its findings in the text reviewed. Private insurance, non-Medicare drug prices, and state-level actions get only light coverage. Treat this as a partial map, not the full territory.

Please seek a professional. This article is general information, not medical advice. Please seek a doctor or other qualified health professional about your own situation. In an emergency, call 911 or your local emergency number.